SCHEMBL3069494

SCHEMBL3069494

CC[C@H](OS(=O)(=O)C(F)(F)F)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2797629 1.00 SMN1; SMN2 (0.35) SMN1; SMN2PTGDR2
SCHEMBL2327079 1.00 SMN1; SMN2 (0.35) SMN1; SMN2PTGDR2
SCHEMBL2323353 0.85 F2 (0.32)
SCHEMBL700951 0.85 HDAC1 (0.39)
SCHEMBL701747 0.85 HDAC1 (0.39)
SCHEMBL15619096 0.85 HDAC1 (0.39)
SCHEMBL2326461 0.83 HSD17B10 (0.35) SMN1; SMN2PTGDR2
SCHEMBL21261493 0.83 CA1 (0.38) SMN1; SMN2
SCHEMBL15922161 0.83 HSD17B10 (0.35) SMN1; SMN2PTGDR2
SCHEMBL2332745 0.83 CA1 (0.38) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1852426-B1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND AND INTERMEDIATE OF THE SAME KOWA CO (JP) 2013-11-13 EP disclosed
US-7790903-B2 Process for production of optically active PPAR-activating compound and intermediate of the same KOWA CO., LTD. (JP) 2010-09-07 US disclosed
US-7538242-B2 Optically active PPAR-activating compound intermediate and method for producing same KOWA CO., LTD. (JP) 2009-05-26 US disclosed
US-20090023944-A1 OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND INTERMEDIATE AND METHOD FOR PRODUCING SAME KOWA CO., LTD. (JP) 2009-01-22 US disclosed
US-20080194833-A1 Process For Production of Optically Active Ppar-Activating Compound and Intermediate of the Same KOWA CO., LTD. (JP) 2008-08-14 US disclosed
EP-1854779-A1 OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND INTERMEDIATE AND METHOD FOR PRODUCING SAME Kowa Company, Ltd. (JP) 2007-11-14 EP disclosed
EP-1852426-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND AND INTERMEDIATE OF THE SAME Kowa Company, Ltd. (JP) 2007-11-07 EP disclosed
EP-1852426-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND AND INTERMEDIATE OF THE SAME Kowa Company, Ltd. (JP) 2007-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023944-A1 OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND INTERMEDIATE AND METHOD FOR PRODUCING SAME PPARA, PPARG, PPARD SMN1; SMN2 4832/4885PTGDR2 694/4885
US-20080194833-A1 Process For Production of Optically Active Ppar-Activating Compound and Intermediate of the Same PPARA, PPARG, PPARD SMN1; SMN2 4842/4885PTGDR2 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.